News
The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara ... a proposed biosimilar for Simponi® (golimumab) and Simponi Aria® (golimumab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback